NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NeuroSense Therapeutics Ltd. (NRSN) Stock Analysis

NeuroSense Therapeutics Ltd. (NRSN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NRSN

$2.56

+$0.17 (+7.11%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NRSN with… →

NRSN Key Statistics

As of Oct 21, 2026
Trading
Open
$2.46
Previous Close
$2.39
Day's Range
2.41–2.67
52-Week Range
2.19–25.40
Volume
10.88K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.64
Valuation
Market Cap
$4.86M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−47.10
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$11.13M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.90M
1-Year Return
−89.72%
Dividend and dates
Avg Volume
24.81K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NRSN closed at $2.56, −89.72% over 1 year.

NeuroSense Therapeutics Ltd. (NRSN) has a market capitalization of $4.86M.

In fiscal 2025, NRSN reported revenue of $0.00.

NRSN Stock Return by Calendar Year

NeuroSense Therapeutics Ltd. (NRSN) return since Dec 2021: what $10,000 became

1 year
$10,000 $1,028
−89.72%
3 years
$10,000 $2,607
−73.93%
Since Dec 2021
$10,000 $317
−96.83%

If you had invested $10,000 in NeuroSense Therapeutics Ltd. (NRSN) at the close on December 9, 2021, the earliest close on record here, it would have been worth $317 at the close on October 21, 2026: −96.83% in total, −50.81% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−83.36%
2025−35.92%
2024+52.87%
2023−35.66%
2022−50.41%
2021 (partial year)−39.11%

As of October 21, 2026.

NRSN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$11.13M—
2024$0.00−$10.21M—
2023$0.00−$10.11M—
2022$0.00−$10.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.09M−$11.13M—
2024$0.00—−$9.90M−$10.21M—
2023$0.00—−$12.05M−$10.11M—
2022$0.00—−$10.55M−$10.49M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NeuroSense Therapeutics Ltd. (NRSN) carries a market capitalisation of $4.86M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 17 employees.

NRSN last closed at $2.56 on October 21, 2026. That is +$0.17 (+7.11%) against the previous close. Over the past 52 weeks the price has ranged from $2.19 to $25.40. The latest close sits 16.89% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $11.13M. Earnings per share on a trailing basis come to −47.1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 1.64. Annualized volatility over the trailing 4 years is 102.69%. The trailing one-year total return is −89.72%. Across 3 years the annualized return works out at −36.12%.

Growth & Income

No dividend is on file for NRSN.

So far in 2026 the total return is −83.36%. The strongest complete calendar year on file is 2024 at +52.87%; the weakest is 2022 at −50.41%. Of the 4 complete calendar years on file, 1 finished higher.

Peer Comparison

NeuroSense Therapeutics Ltd. (NRSN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NeuroSense Therapeutics Ltd. NRSN $4.86M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NeuroSense Therapeutics Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Visit website →